FDA Grants Brigatinib Accelerated Approval for Metastatic Non-Small Cell Lung Cancer

On April 28, the FDA granted accelerated approval to the targeted therapy brigatinib (Alunbrig™) for patients with metastatic non-small cell lung cancer (NSCLC) and alterations in the ALK gene whose cancer has progressed during their initial therapy.

Source link

Comments are closed.